“And then the last thing I would say is based on our really strong results this quarter, we're also expecting no change to our full year outlook on earnings for the group business.”

In context

“usiness. So these actions did have an impact on our persistency in the dental block, but we remain disciplined in the market and we did get the rate increases that we required and we walked away from some business that didn't meet our target margins. I would say, as you look forward the dental rate actions are largely behind us at this point. And, in fact, we're seeing the earnings benefit starting to come through our dental earnings. And as you think about the full year both of these effects, the par impact as well as the dental impact will moderate. So you should expect us for a full year reported basis to be back in line with our guidance of 4% to 7%. And you would have had another 100 basis points or so, if you want to look at the underlying numbers, which exclude the power contracts. And then the last thing I would say is based on our really strong results this quarter, we're also expecting no change to our full year outlook on earnings for the group business. Ryan Krueger: Okay. Thank you. Operator: Your next question comes from the line of Suneet Kamath with Jefferies. Please go ahead. Suneet Kamath: Thanks, good morning. Just wanted to ask on the buyback. It was obviously very strong in the first quarter. And in April, it was pretty modest. And I get your comment about kind of catching up to back activity in the fourth quarter. But was there anything in the month of April that was sort of precluding you from maybe leaning in a little bit. I don't know if this VA deal was big enough where you were blacked out. But anything going on with the timing there? Michel Khalaf: Yes. Hi, Suneet, Michel here. No, I think we sort of -- April was sort of in line with -- we did what we set out to do, I would say. So there wasn't any impact from any pending”